Page 2,555«..1020..2,5542,5552,5562,557..2,5602,570..»

First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at …

Posted: November 12, 2012 at 3:42 pm

JERUSALEM--(BUSINESS WIRE)--

Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enrolled in its pilot study of NiCord as an investigational treatment for sickle cell disease (SCD), has been transplanted at Duke University in North Carolina.

Gamida Cell CEO Dr. Yael Margolin said, The NiCord study is a first step in broadening Gamida Cells pipeline of cell therapies to treat patients who suffer from severe non-malignant diseases with a very large unmet clinical need.

SCD is a group of inherited red blood cell disorders where red blood cells become hard and sticky and look like a C-shaped farm tool called a sickle. According to statistics, SCD affects 90,000 to 100,000 in the US alone, mainly African-Americans and Hispanic-Americans. Symptoms range in type and severity. SCD can be fatal and to date, the only cure for SCD is stem cell transplantation from a family related matched donor.

Dr. Margolin continued, Sickle cell disease can be cured with a successful bone marrow transplantation, especially from a family related fully matched donor. Most patients do not pursue this option, since they do not have the suitable donor. NiCord is intended to reverse this situation and provide a readily available cure.

NiCord is an expanded cell graft derived from an entire unit of umbilical cord blood and enriched with stem cells. NiCord was developed based on Gamida Cells proprietary NAM technology.

The official name of the study is Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Sickle Cell Disease. http://www.clinicaltrials.gov/ct2/show/NCT01590628?term=nicord&rank=1. A total of 10 patients, ages 2 21, will be enrolled in the NiCord study, a single center, single arm trial evaluating the safety and efficacy of transplanting NiCord together with a second un-manipulated cord blood unit in patients with SCD following myeloablative therapy. The study will also assess transplant-related mortality, event-free survival and overall survival at 100, 180 and 365 days, respectively.

About Gamida Cell

Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The companys pipeline of stem cell therapy products are in development to treat a wide range of conditions including blood cancers, solid tumors, non-malignant hematological diseases such as hemoglobinopathies, neutropenia and acute radiation syndrome, autoimmune diseases and metabolic diseases as well as conditions that can be helped by regenerative medicine. Gamida Cells therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood, bone marrow and peripheral blood, which are expanded in culture. Gamida Cells current shareholders include: Elbit Imaging (EMITF), Clal Biotechnology Industries (CBI.TA), Israel Healthcare Venture, Teva Pharmaceutical Industries (TEVA), Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: http://www.gamida-cell.com.

Read the rest here:
First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at ...

Posted in Cell Therapy | Comments Off on First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at …

blood banks | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health – Video

Posted: November 12, 2012 at 3:41 pm


blood banks | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health
http://www.cordbloodrecommendation.com Researchers are hopeful that within five years, pieces of the tissue can be used to repair damaged livers and within 15 years, actual liver transplants may be done using lab-grown livers made from cord blood. This is why all of the best companies use the same courier. What is flexing Blood saving?Flex blood caching is a breakthrough in blood caching. As a result, patients can recover faster, thus preventing kidney complications arising from tissue damage. It can be anywhere from about $1500 to about $1800. Following the treatment, David #39;s body created a new blood supply complete with white cells, hence a new immune system. "" Some clinical trials show that the regeneration of the damaged neurons can be done through transplantation of the stem cells in the cord blood. But these are just some diseases from amongst the 70 diseases that can be cured by stem cell, and the list keeps on getting longer. It further saves you from the trouble of locating a matching donor when transplants are concerned. ""Stem cells can be found in multiple locations within our body. -based weekly, that documents breakthrough papers in biotechnology. The umbilical cord is the cord that attaches from the babies belly button to the placenta in the mother #39;s womb during pregnancy. The amount of stem cells is very crucial for any treatment. Private banks on the other hand are for-profit organizations which store blood from the baby for the exclusive use of the donor or donorFrom:loshoteles enmedellinViews:0 0ratingsTime:01:01More inScience Technology

View post:
blood banks | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health - Video

Posted in Biotechnology | Comments Off on blood banks | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health – Video

What Are Stem Cells | Stem Cell Malaysia – Video

Posted: November 12, 2012 at 3:40 pm


What Are Stem Cells | Stem Cell Malaysia
stemcellmalaysia.com Stem cells are non-differentiated cells with the ability to divide and produce any body cell types. The ability of stem cells to differentiate and self-regenerate impart great possibilities for disease treatment other than for restoring health, beauty and anti-aging. Clinically proven for certain illness and conditions, stem cells can now be introduced into the body to repair and replace damaged organ or tissue. For more informative articles on stem cells and stem cell therapy, please visit Stem Cell Malaysia at http:/stemcellmalaysia.com/.From:stemcells2012Views:2 1ratingsTime:06:29More inHowto Style

Originally posted here:
What Are Stem Cells | Stem Cell Malaysia - Video

Posted in Stem Cell Therapy | Comments Off on What Are Stem Cells | Stem Cell Malaysia – Video

City man set to try stem cell therapy

Posted: November 12, 2012 at 3:40 pm

Tags: geoff castle, stem cell therapy

WHEN a serious hip injury looked like slowing down Toowoomba's Geoff Castle, he knew he was facing a life-changing decision.

While cycling around Rottnest Island three years ago, he felt a severe strike of pain in the right side of his groin.

What he initially thought was a soft tissue injury turned out to be far worse.

"It was intense and sudden and I was sure it was just a soft tissue injury," he said.

"I thought I would stretch it out, take some anti-inflammatory drugs and sort it out myself."

However, after multiple consultations, x-rays, physiotherapy and medical treatments, Mr Castle had all but given into the fact that he would need a hip replacement any time in the next 10 years.

But he knew there had to be an alternative, something which would allow him to continue his active life.

Mr Castle began researching alternatives and while doing so, began reading peer-reviewed articles about autologous stem cell treatment.

Geoff Castle is to have stem cell treatment.

Follow this link:
City man set to try stem cell therapy

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on City man set to try stem cell therapy

First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at …

Posted: November 12, 2012 at 3:40 pm

JERUSALEM--(BUSINESS WIRE)--

Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enrolled in its pilot study of NiCord as an investigational treatment for sickle cell disease (SCD), has been transplanted at Duke University in North Carolina.

Gamida Cell CEO Dr. Yael Margolin said, The NiCord study is a first step in broadening Gamida Cells pipeline of cell therapies to treat patients who suffer from severe non-malignant diseases with a very large unmet clinical need.

SCD is a group of inherited red blood cell disorders where red blood cells become hard and sticky and look like a C-shaped farm tool called a sickle. According to statistics, SCD affects 90,000 to 100,000 in the US alone, mainly African-Americans and Hispanic-Americans. Symptoms range in type and severity. SCD can be fatal and to date, the only cure for SCD is stem cell transplantation from a family related matched donor.

Dr. Margolin continued, Sickle cell disease can be cured with a successful bone marrow transplantation, especially from a family related fully matched donor. Most patients do not pursue this option, since they do not have the suitable donor. NiCord is intended to reverse this situation and provide a readily available cure.

NiCord is an expanded cell graft derived from an entire unit of umbilical cord blood and enriched with stem cells. NiCord was developed based on Gamida Cells proprietary NAM technology.

The official name of the study is Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Sickle Cell Disease. http://www.clinicaltrials.gov/ct2/show/NCT01590628?term=nicord&rank=1. A total of 10 patients, ages 2 21, will be enrolled in the NiCord study, a single center, single arm trial evaluating the safety and efficacy of transplanting NiCord together with a second un-manipulated cord blood unit in patients with SCD following myeloablative therapy. The study will also assess transplant-related mortality, event-free survival and overall survival at 100, 180 and 365 days, respectively.

About Gamida Cell

Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The companys pipeline of stem cell therapy products are in development to treat a wide range of conditions including blood cancers, solid tumors, non-malignant hematological diseases such as hemoglobinopathies, neutropenia and acute radiation syndrome, autoimmune diseases and metabolic diseases as well as conditions that can be helped by regenerative medicine. Gamida Cells therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood, bone marrow and peripheral blood, which are expanded in culture. Gamida Cells current shareholders include: Elbit Imaging (EMITF), Clal Biotechnology Industries (CBI.TA), Israel Healthcare Venture, Teva Pharmaceutical Industries (TEVA), Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: http://www.gamida-cell.com.

Read the original:
First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at ...

Posted in Stem Cell Therapy | Comments Off on First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at …

Cell Therapy Industry Group Welcomes its 4,000th member

Posted: November 11, 2012 at 7:59 am

I'm pleased to point out that today the LinkedIn Cell Therapy Industry Group welcomed its 4,000th member today. 


The Cell Therapy Industry group was created to serve as a network of those in the cell therapy industry. The group acts as a vehicle for referrals, networking, information, and facilitating collaboration.  The group's focus is on the activities of companies in and serving the space.


The group began in July 2008. It took 2.5 years to reach the first 1000 members, 9 mos to reach 2,0000, 6 months to reach 3,000, and 6 months to meet today's 4,000 member mark. 


As is typical, there is a very high percentage of passive participants but the group benefits from an avid group of participants who post, share, exchange, and debate on a range of topics ranging from regulatory, clinical, commercial, scientific, manufacturing, financial, and other topics of interest to the group.


As the group has grown I've noted two trends pertaining to the composition of the membership:  (a) having tapped out the c-level suite, growth is increasingly coming from down the hierarchy of the corporate food chain and including those in the operational trenches, and (b) a much higher ratio of new members of late is from outside the US, presumably as LinkedIn increasingly penetrates OUS markets.


We strive hard to maintain the quality of the participation by screening each applicant, deleting off-topic posts, moving promotional posts to the "promotions" tab" and encouraging a balance of news-sharing with useful discussion threads.


I'm proud to say the group has become a vibrant and valuable part of the sector due to the hard work and contributions of all involved.    


As these kind of virtual networks become exponentially larger and provide different value than the professional societies representing the sector, I will be fascinated to watch if and how this affects how sectors like our interact and how this will impact the traditional value proposition of member-based professional societies.


If you are not a member of the LinkedIn Cell Therapy Industry Group, check it out.


--Lee

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/EOlUEgJGsTQ/cell-therapy-industry-group-welcomes.html

Posted in Regenerative Medicine | Comments Off on Cell Therapy Industry Group Welcomes its 4,000th member

Cell Therapy Industry Group Welcomes its 4,000th member

Posted: November 11, 2012 at 7:58 am

I'm pleased to point out that today the LinkedIn Cell Therapy Industry Group welcomed its 4,000th member today. 


The Cell Therapy Industry group was created to serve as a network of those in the cell therapy industry. The group acts as a vehicle for referrals, networking, information, and facilitating collaboration.  The group's focus is on the activities of companies in and serving the space.


The group began in July 2008. It took 2.5 years to reach the first 1000 members, 9 mos to reach 2,0000, 6 months to reach 3,000, and 6 months to meet today's 4,000 member mark. 


As is typical, there is a very high percentage of passive participants but the group benefits from an avid group of participants who post, share, exchange, and debate on a range of topics ranging from regulatory, clinical, commercial, scientific, manufacturing, financial, and other topics of interest to the group.


As the group has grown I've noted two trends pertaining to the composition of the membership:  (a) having tapped out the c-level suite, growth is increasingly coming from down the hierarchy of the corporate food chain and including those in the operational trenches, and (b) a much higher ratio of new members of late is from outside the US, presumably as LinkedIn increasingly penetrates OUS markets.


We strive hard to maintain the quality of the participation by screening each applicant, deleting off-topic posts, moving promotional posts to the "promotions" tab" and encouraging a balance of news-sharing with useful discussion threads.


I'm proud to say the group has become a vibrant and valuable part of the sector due to the hard work and contributions of all involved.    


As these kind of virtual networks become exponentially larger and provide different value than the professional societies representing the sector, I will be fascinated to watch if and how this affects how sectors like our interact and how this will impact the traditional value proposition of member-based professional societies.


If you are not a member of the LinkedIn Cell Therapy Industry Group, check it out.


--Lee

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/EOlUEgJGsTQ/cell-therapy-industry-group-welcomes.html

Posted in Regenerative Medicine | Comments Off on Cell Therapy Industry Group Welcomes its 4,000th member

Biology Of Stem Cells And The Molecular Basis Of The Stem State – Video

Posted: November 11, 2012 at 2:43 am


Biology Of Stem Cells And The Molecular Basis Of The Stem State
ll4.me Biology Of Stem Cells And The Molecular Basis Of The Stem State Biology of Stem Cells and the Molecular Basis of the Stem State concentrates upon adult stem cells, particularly on mesenchymal cell populations, which is the author s area of expertise. The text offers the reader a detailed description of the emergence of stem cell research and the dogmas that were created during the first decades of analysis of stem cell properties, particularly those of hemopoietic stem cells. Biology of Stem Cells and the Molecular Basis of the Stem State also introduces the reader to the commonly accepted notions regarding stem cell biology, with an emphasis on an alternative view of stemness, ie the stem state. In keeping with the popularity of this topic, Biology of Stem Cells and the Molecular Basis of the Stem State addresses the major controversies and points of dispute, among researchers in the stem cell field. Overall, Biology of Stem Cells and the Molecular Basis of the Stem State presents a well-rounded dialogue about stem cells as it not only concentrates upon the biological elements of stem cell, but also addresses the controversy and hype currently enveloping this popular subject. EAN/ISBN : 9781607611301 Publisher(s): Springer, Berlin, Humana Press Discussed keywords: Stammzelle Format: ePub/PDF Author(s): Zipori, Dov Biology of Stem Cells and the Molecular Basis of the Stem State concentrates upon adult stem cells, particularly on mesenchymal cell populations, which ...From:markforbes9854Views:0 0ratingsTime:00:10More inPeople Blogs

Continued here:
Biology Of Stem Cells And The Molecular Basis Of The Stem State - Video

Posted in Stem Cell Research | Comments Off on Biology Of Stem Cells And The Molecular Basis Of The Stem State – Video

Stem Cell Research and TNG – Video

Posted: November 11, 2012 at 2:43 am


Stem Cell Research and TNG
How close is Science to providing visors for the blind? Or what about curing blindness? Have you watched the episode "The Masterpiece Society" from season 5 of TNG? Cause I have a couple of philosophical things to say about that! An article about STEM CELL therapy in regards to vision impairment: abcnews.go.com Interview with TrekMate: http://www.trekmate.org.uk ***I feel like the Star Trek community is a lot bigger then what YouTube has to offer, so I #39;ve started uploading my own videos. A lot of you will find this painfully dorky -and it is- which is why constructive criticism is welcomed. For anyone who does like my posts, thank you! It would be nice to gather a little Trekkie community :)***From:ThatTrekkieGirlViews:6 1ratingsTime:06:51More inPeople Blogs

Visit link:
Stem Cell Research and TNG - Video

Posted in Stem Cell Research | Comments Off on Stem Cell Research and TNG – Video

Coast to Coast AM June 05 2012 Biocentrism and Stem Cell Research – Video

Posted: November 11, 2012 at 2:43 am


Coast to Coast AM June 05 2012 Biocentrism and Stem Cell Research
Coast to Coast AM is a North American (US and Canada) late-night radio talk show that deals with a variety of topics, but most frequently ones that relate to either the paranormal or conspiracy theories. The program currently airs seven nights a week 1:05 am -- 5:00 am Eastern Time (10:05 pm -- 2:00 am Pacific Time). Originally created and hosted by Art Bell, as of 2012 the program is hosted on most nights by George Noory. According to estimates by Talkers Magazine, Coast to Coast AM draws approximately 3 million listeners, making it the most listened-to program in its time slot Format and subject matter The Coast to Coast AM format consists of a combination of live callers and long format interviews. The subject matter covers unusual topics and is full of personal stories related to callers. While program content is often focused on paranormal and fringe subjects, sometimes world class scientists such as Michio Kaku and Brian Greene are featured in long format interviews. Topics discussed include the Near-death experience, climate change, cosmology, quantum physics, remote viewing, hauntings, contact with extraterrestrials, psychic reading, metaphysics, conspiracy theories, Area 51, crop circles, cryptozoology, Bigfoot, the Hollow Earth hypothesis, and science fiction literature, among others. Since the September 11, 2001 attacks, the events of that day (as well as alternate theories surrounding them) and current US counter-terrorism strategy have also become frequent ...From:C2CVAULTViews:0 0ratingsTime:02:34:21More inEducation

Read the rest here:
Coast to Coast AM June 05 2012 Biocentrism and Stem Cell Research - Video

Posted in Stem Cell Research | Comments Off on Coast to Coast AM June 05 2012 Biocentrism and Stem Cell Research – Video

Page 2,555«..1020..2,5542,5552,5562,557..2,5602,570..»